• Home  
  • Alembic Gets USFDA Nod for Binimetinib Tablets
- News

Alembic Gets USFDA Nod for Binimetinib Tablets

Alembic’s Binimetinib Tablets are generic equivalents of Mektovi and are indicated, in combination with encorafenib, for treating certain patients with advanced melanoma and metastatic non-small cell lung cancer (NSCLC) carrying specific BRAF mutations.

Alembic Secures USFDA Final Approval for Generic Mektovi

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Binimetinib Tablets in 15 mg and 45 mg strengths.

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Mektovi Tablets, 15 mg, marketed by Array BioPharma.

Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma harbouring a BRAF V600E or V600K mutation. The combination is also indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) harbouring a BRAF V600E mutation.

Alembic was among the first applicants to submit a substantially complete ANDA with a Paragraph IV certification for the 15 mg strength and the sole first applicant for the 45 mg strength. Following the approval, the company is eligible for 180 days of generic drug exclusivity for both strengths of Binimetinib Tablets.

According to IQVIA, the US market for Binimetinib tablets was estimated at USD 282 million for the 12 months ended September 2026.

With this approval, Alembic’s cumulative ANDA approvals from the USFDA have reached 248, comprising 230 final approvals and 18 tentative approvals.

Earlier this month, Alembic also received USFDA final approval for its ANDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to Alcon Laboratories’ Pataday Once Daily Relief, 0.7%, and is indicated for the temporary relief of itchy eyes caused by pollen, ragweed, grass, animal hair and dander. The product was developed in collaboration with Orbicular Pharmaceutical Technologies.

Alembic reports strong Q2 FY27 performance

Alembic Pharmaceuticals reported strong financial performance for the second quarter and half year ended 30 September 2026.

Revenue from operations increased 36% year-on-year (YoY) to INR 2,603 crore in Q2 FY27, while profit after tax (PAT) rose 81% YoY to INR 335 crore.

Pranav Amin, managing director of Alembic Pharmaceuticals, said the company’s US business delivered an exceptional performance, driven by strong volume growth and new product launches. India regained momentum, while the ex-US and active pharmaceutical ingredient (API) businesses continued their growth trajectories.

He added that improving momentum in chronic therapies was strengthening the quality of growth in the India Branded business, while the US Branded business was gaining traction across its existing portfolio.

“Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders,” Amin said.

About Us

HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.

Contact: +91 9354115542

HealthXploreIndia @2026. All Rights Reserved.